Biochemical Marker Panel for Pre-eclampsia Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting pre-eclampsia (PE) are inadequate, as they often rely on late-stage indicators like blood pressure and proteinuria, lacking sensitivity and specificity, and there is a need for early and accurate prediction to reduce healthcare costs and improve maternal and fetal outcomes.
Innovation Solution
A method involving the determination of specific biochemical markers such as soluble tissue necrosis factor alpha receptor 1 (sTNFαR1), Matrix Metalloproteinase-9 (MMP-9), and placental growth factor (PLGF), combined with haemodynamic markers like diastolic notch in the uterine artery waveform and blood pressure, to predict pre-eclampsia with high sensitivity and specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional detection methods using blood pressure and proteinuria are used, then detection is simple and cost-effective, but sensitivity and specificity are insufficient and detection occurs late
Solution Approach 1:
The detection method is segmented into multiple independent biochemical markers (sTNFαR1, MMP-9, PLGF, PAI-1, PAI-2, leptin, ICAM) that can be measured separately and then combined. Each marker provides specific information about different aspects of pre-eclampsia pathophysiology, allowing for modular testing approaches that can be tailored to clinical needs while maintaining high overall accuracy.
Solution Approach 2:
Multiple biochemical markers are merged into a comprehensive prediction model that combines their individual predictive values. The patent integrates results from various marker assays along with haemodynamic measurements to create a unified risk assessment system, thereby achieving high sensitivity and specificity that exceeds any single marker alone.
2Reliability
If multiple biochemical markers are determined to predict pre-eclampsia, then sensitivity and specificity improve, but testing complexity and cost increase
Solution Approach 1:
The patent allows for partial implementation where clinicians can select subsets of the full marker panel based on individual patient risk factors and clinical circumstances. While the complete model includes seven biochemical markers, the system supports tailored approaches using fewer markers when appropriate, balancing reliability improvement with testing complexity management.
Solution Approach 2:
The prediction model incorporates dynamic parameter changes by measuring markers at multiple time points during pregnancy and adjusting risk assessment as physiological parameters evolve. This temporal dimension allows the system to adapt to changing clinical conditions while maintaining reliability without requiring all markers to be tested simultaneously at every visit.
3Loss of time
If early prediction of pre-eclampsia is achieved, then healthcare resources can be optimized and costs reduced, but requires more sophisticated testing methods
Solution Approach 1:
The biochemical marker panel is designed to detect subclinical changes in placental function and maternal response that precede the onset of overt pre-eclampsia symptoms. By measuring these markers in the second trimester and early third trimester, the system performs preliminary detection of the disease process before blood pressure elevation and proteinuria develop, enabling early intervention.
Solution Approach 2:
The patent replaces mechanical/physical detection methods (blood pressure measurement, urine protein testing, Doppler ultrasound) with biochemical measurement systems that detect molecular markers of disease. This substitution enables detection at the molecular level before physiological changes become apparent through traditional mechanical means, though it requires sophisticated laboratory assays.
Data Source
AI summary
The technology described herein relates to methods of detecting or predicting pre-eclampsia (PE). The technology described herein also relates to commercial packages, such as diagnostic kits, for performing a method of detecting or predicting PE. In particular, the technology described herein provides methods of predicting pre- eclampsia by determining the levels of biochemical markers.